ABCAM PLC Notice of Results (7579Y)

TIDMABC

RNS Number : 7579Y

ABCAM PLC

11 September 2020

11September 2020

ABCAM PLC

("Abcam," the "Company" or the "Group")

Notice of Full Year Results

Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, will report its Full Year Results for the twelve-month period ended 30 June 2020 on 14 September 2020.

Abcam will host a webcast for analysts and investors at midday BST / 7am EDT that day, with an opportunity to ask questions via the conference call line. To register, please contact Mary Whittow at FTI Consulting ([e-mail] / [phone]). Alternatively, details are available via the Investor Relations section of Abcam's website at www.abcamplc.com/investors/reports-presentations/

A replay will also be made available on the Company's website following the event.

Abcam plc

+ 44 (0) 1223 696 000

James Staveley, VP Investor Relations

Numis - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Duncan Monteith / Huw Jeremy

J.P.Morgan Cazenove - Joint Corporate Broker

[phone]

James Mitford / Hemant Kapoor

Morgan Stanley - Joint Corporate Broker

+ 44 (0) 207 425 8000

Tom Perry / Luka Kezic

FTI Consulting

[phone]

Ben Atwell / Natalie Garland-Collins

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated antibodies and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

Please visit www.abcam.com or www.abcamplc.com to find out more.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGCGDCDXBDGGB

(END) Dow Jones Newswires

September 11, 2020 05:34 ET (09:34 GMT)